Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20099859 | 0.94 | KCNH2 (0.50) | KCNH2SMN1; SMN2CCR1CCR8HSD17B3 | |
| SCHEMBL20730272 | 0.92 | KCNH2 (0.53) | KCNH2SMN1; SMN2CCR1CCR8HSD17B3 | |
| SCHEMBL30392101 | 0.88 | SMN1; SMN2 (0.45) | KCNH2SMN1; SMN2CCR1CCR8HSD17B3 | |
| SCHEMBL1632272 | 0.88 | SMN1; SMN2 (0.45) | KCNH2SMN1; SMN2CCR1CCR8HSD17B3 | |
| SCHEMBL4750814 | 0.83 | PPARG (0.41) | KCNH2SMN1; SMN2CCR1CCR8HSD17B3 | |
| SCHEMBL24916774 | 0.83 | CCR1 (0.52) | KCNH2SMN1; SMN2CCR1CCR8HSD17B3 | |
| SCHEMBL30201993 | 0.83 | CCR1 (0.52) | KCNH2SMN1; SMN2CCR1CCR8HSD17B3 | |
| SCHEMBL681574 | 0.82 | KCNH2 (0.64) | KCNH2SMN1; SMN2CCR1CCR8HSD17B3 | |
| SCHEMBL10144469 | 0.81 | KCNH2 (0.54) | KCNH2SMN1; SMN2CCR1CCR8HSD17B3 | |
| SCHEMBL6194712 | 0.80 | KCNH2 (0.47) | KCNH2SMN1; SMN2CCR1CCR8HSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| US-5518860-A | IMPROVED ADHESION TO SILICON OXIDE AND NITRIDE SUBSTRATES | TOKYO OHKA KOGYO CO., LTD. (JP) | 1996-05-21 | — | — | US | claimed |
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2788332-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN, INC. (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2013086229-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-2576510-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011153509-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| US-7534794-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2009-05-19 | — | — | US | disclosed |
| WO-2008147864-A2 | METHODS OF USING PIPERAZINE COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-12-04 | — | — | WO | disclosed |
| CN-1202152-A | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 1998-12-16 | — | — | CN | disclosed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | disclosed |
| US-5763461-A | ANTIPICORNAVIRAL AGENTS | SANOFI (FR) | 1998-06-09 | — | — | US | disclosed |
| US-5618821-A | VIRICIDES, PICORNAVIRUS | SANOFI, S.A. (FR) | 1997-04-08 | — | — | US | disclosed |
| US-5518860-A | IMPROVED ADHESION TO SILICON OXIDE AND NITRIDE SUBSTRATES | TOKYO OHKA KOGYO CO., LTD. (JP) | 1996-05-21 | — | — | US | disclosed |
| WO-1995031438-A1 | THERAPEUTIC PHENOXYALKYLHETEROCYCLES | SANOFI WINTHROP, INC. (US) | 1995-11-23 | — | — | WO | disclosed |
| US-5292757-A | 1,4-dihydropyridine compounds useful as reverse resistance agents | AJINOMOTO COMPANY, INC. (JP) | 1994-03-08 | — | — | US | disclosed |
| US-4457934-A | ESTER DERIVATIVE OF PYRIDINE | STAUFFER CHEMICAL COMPANY (US) | 1984-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | SCN1A, SCN1B, CACNA1B | KCNH2 28/4885SMN1; SMN2 448/4885CCR1 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.